

Prof. Dr. med. Michael P. Schön

Klinische Tätigkeit:

Allgemeine Dermatologie, Allergologie, Dermatohistologie.
Entzündliche Hautkrankheiten (z. B. Schuppenflechte, Neurodermitis),
beruflich bedingte Hautkrankheiten,
Diagnostik und Therapie von Hautkrebs.

Wissenschaftliche Schwerpunkte:

1. Immunregulation bei Entzündungen
2. Pathogenese und Therapie der Psoriasis
3. vaskuläre Funktionen bei entzündlichen Erkrankungen
4. experimentelle Modelle für Psoriasis und andere entzündliche Erkrankungen (Allergien)
5. Therapieresistenz maligner Tumoren (Melanom, epitheliale Tumoren)
6. Wirkmechanismen kleinmolekularer Substanzen bei der Tumortherapie
7. Therapeutische Modulation intrazellulärer Signalwege
8. Nanostrukturelle Regulation von Tumorzell-Funktionen

Forschungsförderung:

Europäische Union, Deutsche Forschungsgemeinschaft, Deutsche
Krebshilfe, Wilhelm-Sander-Stiftung, VW-Stiftung, Industrie

Michael P. Schön, M.D.

Clinical spectrum:

general dermatology, allergology, dermatopathology
chronic inflammatory disorders (e.g., psoriasis, atopic dermatitis, contact allergy),
occupational dermatology,
skin cancer (diagnosis, prevention, therapy)

Scientific profile:

1. immune regulation in inflammation
2. pathogenesis and therapy of psoriasis
3. vascular functions in inflammatory disorders
4. preclinical experimental models for psoriasis and other inflammatory disorders (allergies)
5. tumor resistance against therapy (melanoma, epithelial tumors)
6. mode of action of small molecule compounds in tumor therapy
7. therapeutic modulation of intracellular signaling
8. nanostructural regulation of tumor cell functions

Funding:

European Union, Deutsche Forschungsgemeinschaft, Wilhelm-Sander-
Stiftung, VW-Stiftung, Industry

10 MOST IMPORTANT PUBLICATIONS

Amschler K, Erpenbeck L, Kruss S, **Schön MP**: Nanoscale Integrin Ligand Patterns Determine Melanoma Cell Behavior. **ACS Nano**. 8(9), 9113-9125, 2014; doi.10.1021/nn502690b.

Kruss S*, Erpenbeck L*, Amschler K, Munding TA, Boehm H, Helms HJ, Andrews RK, **Schön MP***, Spatz JP*: Adhesion maturation of neutrophils on naoscopically presented platelet receptor GPIIb/IIIa. **ACS Nano**. 7(11), 9984-9996, 2013; doi: 10.1021/nn403923h. **equal contribution*

Zibert JR*, Wallbrecht K*, Schön M, Mir LL, Jacobsen GK, Trochon-Joseph V, Bouquet C, Villadsen LS, Cadossi R, Skov L*, **Schön MP***: Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. **J. Clin. Invest.** 121(1), 410-421, 2011; doi: 10.1172/JCI41295. **equal contribution*

Schön M, Wienrich BG, Kneitz S, Schlickum S, Sennefelder H, Amschler K, Vöhringer V, Hüttinger-Kirchhof N, Stiewe T, Ziegelbauer K, **Schön MP**: KINK-1, a novel small-molecule inhibitor of IKK β , and the susceptibility of melanoma cells to antitumoral treatment. **J. Natl. Cancer Inst.** 100, 862-875, 2008; doi: 10.1093/jnci/djn174.

Erpenbeck L, **Schön MP**: Deadly allies: the fatal interplay between platelets and metastasizing tumor cells. **Blood**, 115(17), 3427-3436, 2010; doi: 10.1182/blood-2009-10-247296.

Schlickum S, Sennefelder H, Friedrich M, Harms G, Lohse MJ, Kilshaw P, **Schön MP**: Integrin $\alpha_E(CD103)\beta_7$ influences cellular shape and motility in a ligand-dependent fashion. **Blood** 112, 619-625, 2008; doi: 10.1182/blood-2008-01-134833.

Schön MP, Boehncke WH: Psoriasis. **New Engl. J. Med.** 352, 1899-1912, 2005

Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, **Schön MP**: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. **J. Natl. Cancer Inst.** 95, 1138-1149, 2003

Schön MP, Krahn T, Schön M, Rodriguez M-L, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm K-D, Schramm M, Henninger K, Kaufmann R, Gollnick HPM, Parker CM, Boehncke W-H: Efomycine M, a novel specific selectin inhibitor, impairs leukocyte adhesion and alleviates cutaneous inflammation. **Nat. Med.** 8, 366-372, 2002

Schön MP, Detmar M, Parker CM: Murine psoriasis-like disorder induced by naive CD4⁺ T cells. **Nat. Med.** 3: 183-188, 1997

Publications in the year 2014

a) Experimental original publications

1. Amschler K, Erpenbeck L, Kruss S, **Schön MP**: Nanoscale Integrin Ligand Patterns Determine Melanoma Cell Behavior. **ACS Nano**. 8(9), 9113-9125, 2014; doi:10.1021/nn502690b.
2. Schneider P*, Schön M*, Pletz N, Seitz CS, Liu N, Ziegelbauer K, Zachmann K, Emmert S, **Schön MP**: The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro. **Exp. Dermatol.** 23(8), 579-584, 2014, doi: 10.1111/exd.12470. **equal contribution*
3. Forkel S*, Schön M*, Hildmann A, Claßen A, John SM, Danker K, **Schön MP**: Inositolated Platelet Activating Factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models. **J. Invest. Dermatol.**, 2014; doi: 10.1038/jid.2014.170,; **equal contribution*
4. Buhl T, Braun A, Forkel S, Möbius W, van Werven L, Jahn O, Rezaei-Ghaleh N, Zweckstetter M, Mempel M, **Schön MP**, Haenssle HA: Internalization routes of Cell-penetrating Melanoma Antigen Peptides into Human Dendritic Cells. **Exp. Dermatol.** 23(1), 20-26, 2014; doi: 10.1111/exd.12285.
5. Semini G, Hildmann A, Klein A, Lucka L, Schön M, **Schön MP**, Shmanai V, Danker K: Inositol-C2-PAF down-regulates components of the antigen presentation machinery in a 2D-model of epidermal inflammation. **Biochem. Pharmacol.**, 87(3), 477-488, 2014; doi: 10.1016/j.bcp.2013.11.012.
6. Lorenz V, **Schön MP**, Seitz CS: c-Rel downregulation affects cell cycle progression of human keratinocytes. **J. Invest. Dermatol.** 134(2), 415-422, 2014; doi: 10.1038/jid.2013.315.
7. Lockmann A, **Schön MP**: TNF α -induced leukocyte-endothelial cell interactions show marked inter-individual differences independent of the clinical response to adalimumab. **Exp. Dermatol.** 23(2), 133-134, 2014; doi: 10.1111/exd.12283.

b) Clinical original publications

8. Kretschmer L, Bertsch HP, Bardzik P, Meller J, Hellriegel S, Thoms KM, Schön MP, Sahlmann O: The impact of nodal tumour burden on lymphoscintigraphic imaging in patients with melanomas. **Eur. J. Nucl. Med. Mol. Imag.** In press, 2014.
9. Kaune KM, Lauerer P, Kietz S, Eich C, Thoms KM, **Schön MP**, Zutt M: Combination therapy of infantile hemangiomas with pulsed dye laser and Nd:YAG laser is effective and safe. **J. Dtsch. Dermatol. Ges.** 12(6), 473-478, 2014; doi: 10.1111/ddg.12354.
10. Mitteldorf C, Bertsch HP, Jung K, Thoms KM, **Schön MP**, Tronnier M, Kretschmer L: Sentinel node biopsy improves prognostic stratification in patients with thin (pT1)

melanomas and an additional risk factor. *Ann. Surg. Oncol.* 21(7):2252-2258, 2014; doi: 10.1245/s10434-014-3641-6.

11. Brehmer F, Haenssle HA, Däschlein G, Raees A, Pfeiffer A, Görlitz A, Simon D, **Schön MP**, Wandke D, Emmert S: Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm® VU-2010): Results of a monocentric, two-armed, open, prospective, randomized, and controlled trial (NCT01415622). *J. Eur. Acad. Dermatol. Venereol.* doi: 10.1111/jdv.12490, 2014
12. Haenssle HA, Hoffmann S, Holzkamp R, Samhaber K, Lockmann A, Fliesser M, Emmert S, **Schön MP**, Rosenberger A, Buhl T: Melanoma thickness: The role of patients` characteristics, risk indicators and patterns of diagnosis. *J. Eur. Acad. Dermatol. Venereol.* 2014; doi: 10.1111/jdv.12471, 2014
13. Al Ghazal P, Gutzmer R, Satzger I, Starz H, Bader C, Thoms KM, Mitteldorf C, **Schön MP**, Kapp A, Bertsch HP, Kretschmer L: Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas. *Melanoma Res.* 24(2), 158-164, 2014; doi: 10.1097/CMR.0000000000000042.

c) Clinical case reports

14. Grönemeyer LL, Stamatopoulos K, Holzkamp R, **Schön MP**, Thoms KM: Embedded earring back mistaken for ear lobe keloid in an eight-year-old girl. *J. Dtsch. Dermatol. Ges.* 12(9), 813-814, 2014, doi: 10.1111/ddg.12340
15. Samhaber K, Haenssle HA, Mempel M, **Schön MP**, Thoms KM: Multiple annular erythematous lesions in a 9-year-old boy. *J. Dtsch. Dermatol. Ges.* 12(8), 731-733, 2014; doi: 10.1111/ddg.12322.
16. Hüffmeier U, Wätzold M, Mohr J, **Schön MP**, Mössner R: Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. *Br. J. Dermatol.* 170(1), 202-204, 2014; doi: 10.1111/bjd.12548.
17. Jantke M, Has C, Haenssle HA, **Schön MP**, Emmert S: Epidermolysis bullosa simplex: Greater penetrance due to a keratin 5 gene variant. *Clin. Exp. Dermatol.* 39(1), 80-81, 2014; doi: 10.1111/ced.12175.
18. Wolff CR, Brehmer F, Lockmann A, Brauns B, **Schön MP**, Emmert S, Haenssle HA,: Rapidly growing bluish nodule on the left cheek of a 4-year old boy. *J. Dtsch. Dermatol. Ges.* 12(5):432-434, 2014; doi: 10.1111/ddg.12281.
19. Brehmer F, Lockmann A, Wolff C, Hofmann L, **Schön MP**, Emmert S, Haenssle HA: Grouped vesicles with brown background pigmentation on the abdomen of a 9-year-old girl. *J. Dtsch. Dermatol. Ges.* 12(4), 362-364, 2014; doi: 10.1111/ddg.12235_suppl.
20. Hellriegel S, Bertsch HP, Emmert S, **Schön MP**, Haenssle HA: Elastosis perforans serpiginosa – A case of a penicillamine-induced degenerative dermatosis. *JAMA Dermatol.* 150(7), 785-787, 2014; doi: 10.1001/jamadermatol.2013.8635.

d) Reviews, Editorials, Guidelines

21. **Schön MP**: The plot thickens while the scope broadens: A holistic view on IL-17 in psoriasis and other inflammatory disorders. *Exp. Dermatol.* in press, 2014; doi: 10.1111/exd.12541.
22. Emmert S, **Schön MP**, Haenssle HA: Molecular biology of basal and squamous cell carcinomas. *Adv. Exp. Med. Biol.* 810, 234-52, 2014.
23. Kaufmann R, Enk A, **Schön MP**, Goerdts S: 125 Jahre – und kein bisschen leise. *J. Dtsch. Dermatol. Ges.* 12(1), 1-2, 2014; doi: 10.1111/ddg.12276.
24. Emmert S, Brehmer F, Hänssle HA, Helmke A, Mertens N, Ahmed R, Simon D, Wandke D, **Schön MP**, Maus-Friedrichs W, Viöl W, Däschlein G: Treatment of chronic venous leg ulcers with a hand-held DBD plasma generator. *Plasma Med.*, in press, 2014

e) Book chapters

25. Emmert S, **Schön MP**, Haenssle HA: Molecular Biology of basal and squamous cell carcinomas. In: Reichrath J (Ed.): *Sunlight, Vitamin D and Skin Cancer*, 2nd edition, Landes Bioscience and Springer, 234-252, 2014

Publications in the year 2013

a) Experimental original publications

26. Kruss S*, Erpenbeck L*, Amschler K, Mundinger TA, Boehm H, Helms HJ, Andrews RK, **Schön MP***, Spatz JP*: Adhesion maturation of neutrophils on naoscopically presented platelet receptor GPIIb α . *ACS Nano.* 7(11), 9984-9996, 2013; doi: 10.1021/nn403923h. *equal contribution
27. Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Sørensen CS, Gaestel M, Helleday T, **Schön MP**, Döbelstein M: Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. *Proc. Natl. Acad. Sci. USA.* 110(42), 16856-16861, 2013; doi: 10.1073/pnas.1304355110.
28. Streckfuss-Bömeke K, Wolf F, Azizian A, Stauske M, Tiburcy M, Wagner S, Hübscher D, Dressel R, Chen S, Jende J, Wulf G, Lorenz V, **Schön MP**, Maier LS, Zimmermann WH, Hasenfuss G, Guan K: Comparative study of human induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes and skin fibroblasts. *Eur. Heart J.* 34(33), 2618-2629, 2013; doi: 10.1093/eurheartj/ehs203.
29. Kotzerke C, Mempel M, Aung T, Wulf GG, Urlaub H, Wenzel D, **Schön MP**, Braun A: Immunostimulatory activity of murine keratinocyte-derived exosomes. *Exp. Dermatol.* 22(10), 650-655, 2013; doi: 10.1111/exd.12230.

30. Glauer J, Pletz N, Schön M, Schneider P, Liu N, Ziegelbauer K, Emmert S, Wulf GG, **Schön MP**: A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma *in vitro* and *in vivo*. **Blood Cancer J.** 3, e141, 2013; doi:10.1038/bcj.2013.37.
31. Schäfer A, Gratchev A, Seebode C, Hofmann L, Schubert S, Laspe P, Apel A, Ohlenbusch A, Tzvetkov M, Weishaupt C, Oji V, **Schön MP**, Emmert S: Functional and molecular genetic analyses of nine newly identified XPD-deficient patients reveal a novel mutation resulting in TTD as well as in XP/CS complex phenotypes. **Exp. Dermatol.** 22(7), 486-489, 2013; doi: 10.1111/exd.12166.
32. Frantz S, Hofmann U, Fraccarollo D, Schäfer A, Kranepuhl S, Hagedorn I, Nieswandt B, Nahrendorf M, Wagner H, Bayer B, Pachel C, **Schön MP**, Kneitz S, Ertl G, Bauersachs J: Monocytes/ macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. **FASEB J.** 27(3), 871-881, 2013; doi: 10.1096/fj.12-214049.
33. Schäfer A, Schubert S, Gratchev A, Seebode C, Apel A, Laspe P, Hofmann L, Ohlenbusch A, Mori T, Kobayashi N, Schürer A, **Schön MP**, Emmert S: Characterization of 3 XPG-defective patients identifies 3 missense mutations that impair repair and transcription. **J. Invest. Dermatol.** 133(7), 1841-1849, 2013; doi: 10.1038/jid.2013.54.
34. Lockmann A, **Schön MP**: Phenotypic and functional traits of PBMC retained by controlled cryopreservation: Implications for reliable sequential studies of dynamic interactions with endothelial cells. **Exp. Dermatol.** 22(5), 358-359, 2013; doi: 10.1111/exd.12123.
35. Schäfer A, Hofmann L, Gratchev A, Laspe P, Schubert S, Schürer A, Ohlenbusch A, Tzvetkov M, Hallermann C, Reichrath J, **Schön MP**, Emmert S: Molecular genetic analysis of 16 XP-C patients from Germany: environmental factors predominately contribute to phenotype variations. **Exp. Dermatol.** 22(1), 24-29, 2013; doi: 10.1111/exd.12052.
36. Singh TP, **Schön MP**, Wallbrecht K, Gruber-Wackernagel A, Wang XJ, Wolf P: Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. **PlosOne.** 8 (1), e51752, 2013; doi: 10.1371/journal.pone.0051752.

b) Clinical original publications

37. Haenssle HA, Ayad N, Buhl T, Rosenberger A, Thoms KM, **Schön MP**, Zutt M: Limited diagnostic value of Wells Score and D-dimer testing in hospitalized dermatologic patients with symptoms of deep vein thrombosis. **Eur. J. Dermatol.**, 23(6), 830-836, 2013; doi: 10.1684/ejd.2013.2188.
38. Kaune KM, Haas E, Jantke M, Kramer FJ, Gruber R, Thoms KM, **Schön MP**, Zutt M: Successful Nd:YAG Laser Therapy for Hair Removal in the Oral Cavity after Plastic Reconstruction Using Hairy Donor Sites. **Dermatology** 226(4), 324-328, 2013; doi: 10.1159/000350685.

39. Kretschmer L, Sahlmann CO, Bardzik P, Mitteldorf C, Helms HJ, Meller J, **Schön MP**, Bertsch HP: Individualized surgery: Gamma-probe guided lymphadenectomy in patients with clinically enlarged lymph node metastases from melanomas. *Ann. Surg. Oncol.* 20(5), 1714-1721, 2013; doi: 10.1245/s10434-012-2841-1.

c) Clinical case reports

40. Brehmer F, Zutt M, Lockmann A, **Schön MP**, Thoms KM: Nd:YAG laser epilation to prevent recurrences after pilonidal sinus surgery. *J. Dtsch. Dermatol. Ges.* 11(12), 1203-1205, 2013; doi: 10.1111/ddg.12227.
41. Lockmann A, Brehmer F, Hofmann L, Wolff C, Emmert S, **Schön MP**, Brauns B, Haenssle HA: Brown macule with parallel ridge pattern on the palm of a 58-year-old woman. *Hautarzt* 64(12) 946-948, 2013; doi: 10.1007/s00105-013-2669-z.
42. Herink C, Zwaka PA, **Schön MP**, Mempel M, Seitz CS: Serious complications following gluteal injection of silicone. *Hautarzt* 64(8), 599-602, 2013; doi: 10.1007/s00105-013-2573-6.
43. Kaune KM, Zutt M, Stein H, Gesk S, **Schön MP**, Bertsch HP: Solid variant of angiomatoid fibrous histiocytoma masked by interstitial granuloma annulare in a 13-year old child: no evidence for translocation breakpoints. *Acta Dermatol. Venereol.* 94(3), 353-4, 2013; doi: 10.2340/00015555-1698.
44. Quack H, Erpenbeck L, Wolff HA, Sprenger T, Seitz CS, **Schön MP**, Neumann S, Stanek K, Ghadimi BM, Michels B, Middel P, Schaefer IM, Liersch T, Conradi LC: Oxaliplatin-induced leukocytoclastic vasculitis under adjuvant chemotherapy for colorectal cancer: Two cases of a rare adverse event. *Case Rep. Oncol.* 6(3), 609-615, 2013; doi: 10.1159/000357166.
45. Amschler K, **Schön MP**, Mempel M, Zutt M: Atypical location of lymphocytoma cutis in a child. *Pediatr. Dermatol.* 30(5), 628-629, 2013; doi: 10.1111/pde.12166.
46. Brauns B, Mempel M, **Schön MP**, Seitz CS: Multiple Slowly Growing Nodular Lesions on the Lower Legs in a 78-Year-Old Obese Woman-Quiz Case. *JAMA Dermatol.* 149(7), 867-868, 2013; doi: 10.1001/jamadermatol.2013.3377a.
47. Brehmer F, Seitz CS, Schwarz A, Engelke C, Haenssle HA, **Schön MP**, Emmert S: Dermatological features identifying a new family with the cancer-prone Birt-Hogg-Dube syndrome. *Clin. Exp. Dermatol.* 38(8), 931-932, 2013; doi: 10.1111/ced.12145.
48. Brauns B, **Schön MP**, Mempel M: Papulopustular eruption after holiday in a 44-year-old man. *J. Dtsch. Dermatol. Ges.* 11(8), 763-764, 2013; doi: 10.1111/ddg.12049.
49. Weishaupt J, **Schön MP**, Bröcker EB, Kerstan A: Multiple large flaccid purulent blisters in a patient with metastatic breast cancer. *J. Dtsch. Dermatol. Ges.* 11(3), 267-269, 2013; doi: 10.1111/j.1610-0387.2012.08056.x.

d) Reviews, Editorials, Guidelines

50. Boehncke WH, **Schön MP**: Sein oder nicht Sein: Eine weitere Runde in der Diskussion um die Rolle der Psoriasis als Risikofaktor für assoziierte Erkrankungen. *J. Dtsch. Dermatol. Ges.* 11(12), 1133-1134, 2013; doi: 10.1111/ddg.12243.
51. Wohlrab J, Fiedler G, Gerdes S, Nast A, Philipp S, Radtke MA, Thaci D, Koenig W, Pfeiffer AFH, Härter M, **Schön MP**: Recommendations for detection of individual risk for comorbidities in patients with psoriasis. *Arch. Dermatol. Res.* 305(2), 91-98, 2013; doi: 10.1007/s00403-013-1318-9.
52. **Schön MP**: Die Bedeutung von Stiftungen für die Hochschulmedizin (The impact of public-law foundations in academic medicine). *Akt. Dermatol.* 39, 1-3, 2013

Publications in the year 2012

a) Experimental original publications

53. Kruss S, Erpenbeck L, **Schön MP**, Spatz JP: Circular, nanostructured and biofunctionalized hydrogel microchannels for dynamic cell adhesion studies. *Lab. Chip* 12(18), 3285-3289, 2012; doi: 10.1039/c2lc40611j.
54. Schäfer A, Emmert S, Kruppa J, Schubert S, Tzvetkov M, Mössner R, Reich K, Berking C, Volkenandt M, Pfohler C, **Schön MP**, Vogt T, König IR, Reichrath J: No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case-control study. *Arch. Dermatol. Res.* 304(5), 353-361, 2012; doi: 10.1007/s00403-012-1243-3.
55. Buhl T, Legler TJ, Rosenberger A, Schardt A, **Schön MP**, Haenssle HA: Controlled-rate freezer cryopreservation of highly concentrated peripheral blood mononuclear cells results in higher cell yields and superior autologous T-cell stimulation for dendritic cell-based immunotherapy. *Cancer Immunol. Immunother.* 61(11), 2021-2031, 2012; doi: 10.1007/s00262-012-1262-0.
56. Pletz N*, Schön M*, Ziegelbauer K, Emmert S, Liu N, Dobbstein M, **Schön MP**: Doxorubicin-induced activation of NF- κ B in melanoma cells is abrogated by specific inhibition of IKK β , but not by a novel IKK α inhibitor. *Exp. Dermatol.* 21(4), 301-304, 2012; doi: 10.1111/j.1600-0625.2012.01440.x., **equal contribution*
57. Kuschal C, Thoms KM, Schubert S, Schäfer A, Boeckmann L, **Schön MP**, Emmert S: Skin cancer in organ transplant recipients: Effects of immunosuppressive medications on DNA repair. *Exp. Dermatol.* 21, 2-6, 2012; doi: 10.1111/j.1600-0625.2011.01413.x.
58. Singh TP, **Schön MP**, Wallbrecht K, Wolf P: 8-Methoxypsoralen plus UVA treatment increases the proportion of CLA+CD25+CD4+ T cells in lymph nodes of K5.hTGF β 1 transgenic mice. *Exp. Dermatol.* 21(3), 228-230, 2012; doi: 10.1111/j.1600-0625.2011.01437.x.
59. Schill T*, **Schön MP***, Pletz N, Emmert S, Schön M: Stimulation of pulmonary immune responses by the TLR2/6 agonist MALP-2 and effect on melanoma metastasis to the lung. *Exp. Dermatol.* 21(2), 91-98, 2012, doi: 10.1111/j.1600-0625.2011.01386.x., **equal contribution*

b) Clinical publications

60. Bader O, Weig MS, Gross U, **Schön MP**, Mempel M, Buhl T: A 32-year-old man with ulcerative mucositis, skin lesions and nail dystrophy. *Clin. Infect. Dis.* 54(7), 972, 1035-1036, 2012; doi: 10.1093/cid/cir958.
61. Kraus SL, Emmert S, **Schön MP**, Haenssle HA: The dark side of beauty: Acne fulminans induced by anabolic steroids in a male bodybuilder. *Arch. Dermatol.* 148(10), 1210-1212, 2012; doi: 10.1001/archdermatol.2012.855.
62. Brauns B, Seitz CS, **Schön MP**, Mempel M: Sunlight-induced papulovesicular eruption in an 8-year-old girl. *J. Dtsch. Dermatol. Ges.* 10(12), 923-924, 2012; doi: 10.1111/j.1610-0387.2012.08032.x.
63. Jantke ME, **Schön MP**, Kretschmer L, Thoms KM: Diffuse melanosis in a patient with multifocal liver and thyroid metastases of a malignant melanoma. *J. Dtsch. Dermatol. Ges.* 10(10), 764-765, 2012; doi: 10.1111/j.1610-0387.2012.07988.x.
64. Haenssle HA, Buhl T, Holzkamp R, **Schön MP**, Kretschmer L, Bertsch HP: Squamomelanocytic tumor of the nail unit metastasizing to sentinel lymph node: a dermoscopic and histologic investigation. *Dermatology* 225(2), 127-130, 2012; doi: 10.1159/000342181.
65. Brauns B, **Schön MP**, Bertsch HP: Violaceous and Ulcerated Plaque following a Caesarean Section. *Arch. Dermatol.* 165(6), 1160-1161, 2012; doi: 10.1001/archdermatol.2012.2964a.
66. Buhl T, Shoukier M, Grzmil P, Revencu N, **Schön MP**, Seitz CS.: Multifocal Capillary Malformations due to *RASA1* mutation misdiagnosed as Cutaneous Mastocytosis. *Arch. Dermatol* 148(11), 1334-1335, 2012; doi: 10.1001/archdermatol.2012.2835.
67. Mitteldorf C, Tronnier M, Merz H, Hänssle H, Bertsch HP, **Schön MP**, Kaune KM: Insect bite-like reactions in a patient with B-CLL: FISH analysis revealed neoplastic B-cells within the skin infiltrate. *Br. J. Dermatol.* 165(6), 1160-1161, 2012; doi: 10.1111/j.1365-2133.2012.10966.x.
68. Buhl T, Hansen-Hagge C, Korpas B, Kaune KM, Haas E, Rosenberger A, **Schön MP**, Emmert S, Hänssle HA: Integrating static and dynamic features of melanoma: The DynaMel algorithm. *J. Am. Acad. Dermatol.* 66(1), 27-36, 2012; doi: 10.1016/j.jaad.2010.09.731.

c) Reviews, Editorials, Guidelines

69. John SM, **Schön MP**: Occupational dermatology: congratulations to an early victory. *J. Dtsch. Dermatol. Ges.* 10(5), 291-292, 2012
70. Mrowietz U, Adamczyk A, Augustin M, Boehncke WH, Bonnekoh B, Gambichler T, Hengge U, Lippert U, Ludwig RJ, Luger T, Merk HF, Norgauer J, Philipp S, Reich K, Röcken M, Rostami-Yazdi M, **Schön MP**, Scola N, Sticherling M, Thaci D, Viehweg A, Wallbrecht K, Wozel G, Zouboulis CC, Neureither M: Neue Erkenntnisse zu

Fumarsäureestern: Ergebnisse eines Experten-Workshops. *J. Dtsch. Dermatol. Ges.* 9(Suppl. 4), 1-15, 2012; doi: 10.1111/j.1610-0379.2012.08047.x.

71. **Schön MP**: Zukunft der Psoriasis-Therapie. *Akt. Dermatol.* 38, 88-90, 2012

Publications in the year 2011

a) Experimental original publications

72. Zibert JR*, Wallbrecht K*, Schön M, Mir LL, Jacobsen GK, Trochon-Joseph V, Bouquet C, Villadsen LS, Cadossi R, Skov L*, **Schön MP***: Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. *J. Clin. Invest.* 121 (1), 410-421, 2011; *equal contribution
73. Wallbrecht K*, Drick N*, Hund AC, **Schön MP**: Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. *Exp. Dermatol.* 20(12), 980-985, 2011, *equal contribution
74. Singh TP, Huettner B, Koefeler H, Mayer G, Wallbrecht K, **Schön MP**, Wolf P: Platelet-activating factor blockade inhibits Th17 pathway and suppresses psoriasis-like skin disease in K5.hTGF-beta1 transgenic mice. *Am. J. Pathol.* 178(2), 699-708, 2011
75. Kuschal C, Thoms KM, Boeckmann L, Laspe P, Apel A, **Schön MP**, Emmert S: Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins which is mediated by calcineurin inhibition. *Exp. Dermatol.* 20(10), 795-799, 2011
76. Boeckmann L, Nickel AC, Kuschal C, Schaefer A, Thoms KM, **Schön MP**, Thomale J, Emmert S: Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. *Melanoma Res.* 21(3), 206-216, 2011
77. Kaune K, Neumann C, Hallermann C, Haller F, **Schön MP**, Middel P: Simultaneous aberrations of single CDKN2A network components and a high Rb-phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas. *Exp. Dermatol.* 20(4), 331-335, 2011
78. Thoms KM, Kuschal C, Oetjen E, Mori T, Kobayashi N, Laspe P, Böckmann L, **Schön MP**, Emmert S: Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: Implications for tumorigenesis under immunosuppression. *Exp. Dermatol.* 20(3), 232-236, 2011
79. **Schön MP**, Bennemann A, Emmert S, Schultz M: Ergebnisse der histologischen Untersuchungen der Haut der Moorleiche „Moora“. In: A. Bauerochse, H. Haßmann, K. Püschel, M. Schultz, M. (Hrsg.), „Moora“ – Das Mädchen aus dem Uchter Moor. Eine Moorleiche der Eisenzeit aus Niedersachsen II. *Materialhefte zur Ur- und Frühgeschichte Niedersachsens*, Bd. XX. Rahden/Westf. 2011

80. **Schön MP**, Bennemann A, Emmert S, Schultz M: Histologische Untersuchungen der Haut der Moorleiche „Junge von Kayhausen“. *Museumsjournal Natur und Mensch* 6, 113-121, Oldenburg, 2011

b) Clinical publications

81. Buhl T, Meynberg HC, Kaune KM, Hünecke P, **Schön MP**, Fuchs T: Long-term follow-up in patients with NSAID hypersensitivity reveals significant shortcomings in patients' compliance and medical care. *J. Allergy Clin. Immunol.* 127(1), 284-285, 2011
82. Brehmer F, Haenssle HA, **Schön MP**, Emmert S: Response of recalcitrant lichen planus to alitretinoin in 3 patients. *J. Am. Acad. Dermatol.* 65(2), e58-60, 2011
83. Jung AG, Horny HP, Sotlar K, Overbeck T, **Schön MP**, Lippert U: Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. *J. Am. Acad. Dermatol.* 65(1), 224-226, 2011
84. Hänsfle HA, Richter A, Buhl T, Haas E, Holzkamp R, Emmert S, **Schön MP**: Induction of pigmented basal cell carcinomas after orbital radiation therapy for Graves' Ophthalmopathy. *J. Am. Acad. Dermatol.* 147(4), 511-512, 2011
85. Thoms KM, Hellriegel S, Krone B, Beckmann I, **Schön MP**, Bertsch HP, Kretschmer L: Successful treatment of classic Kaposi's sarcoma with low-dose intramuscular immunoglobulins. *Brit. J. Dermatol.* 164(5), 1107-1109, 2011
86. Zutt M, Krüger U, Rosenberger A, **Schön MP**, Neumann C, von Ahsen N, Kretschmer L: Thrombophilia in patients with chronic venous leg ulcers- a study on patients with or without postthrombotic syndrome. *J. Eur. Acad. Dermatol. Venereol.* 25(12), 1432-1439, 2011
87. Krüger U, Kretschmer L, Thoms KM, Padeken M, Bertsch HP, Neumann C, **Schön MP**, Zutt M: Lymph node ultrasound during melanoma follow-up significantly improves metastasis detection as compared to clinical examination alone – a study on 433 patients. *Melanoma Res.* 21(5), 457-463, 2011
88. Brauns B, **Schön MP**, Zutt M: Ulcerative necrobiosis lipoidica successfully treated by vacuum-assisted closure therapy. *Eur. J. Dermatol.* 21(5), 791-792, 2011
89. Jantke ME, Bertsch HP, **Schön MP**, Fuchs T: Treatment of disseminated granuloma annulare with anthralin. *Hautarzt* 62(12), 935-939, 2011
90. Brauns B, Stahl M, **Schön MP**, Zutt M: Intralesional steroid injection alleviates nail lichen planus. *Int. J. Dermatol.* 50(5), 626-627, 2011
91. Meyersburg D, **Schön MP**, Bertsch HP, Seitz CS: Uncommon cutaneous ulcerative and systemic sarcoidosis: Successful treatment with hydroxychloroquine and compression therapy. *Hautarzt* 62(9), 691-695, 2011

92. Goppold A, Kaune KM, Buhl T, **Schön MP**, Zutt M: 595 nm pulsed dye laser combined with intralesional corticosteroids in hypertrophic symptomatic scars following breast reduction surgery. *Eur. J. Dermatol.* 21(2), 262-263, 2011
93. Zutt M, Krüger U, Rosenberger A, **Schön MP**, Neumann C, von Ahsen N, Kretschmer L: Lipoprotein (a) elevation in patients with chronic venous leg ulcers: a prospective study on patients with or without postthrombotic syndrome. *Wound Repair Regen.* 19(2), 168-172, 2011
94. Mitteldorf C, Bertsch HP, Baumgart M, Wulf C, **Schön MP**, Rosenwald A, Neumann C, Kaune KM: Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q. *J. Eur. Acad. Dermatol.* 25(10), 1225-1229, 2011
95. Brehmer D, **Schön MP**: Endonasal phototherapy significantly alleviates symptoms of allergic rhinitis, but has a limited impact on the nasal mucosal immune cells. *Eur. Arch. Otorhinolaryngol.* 268(3), 393-396, 2011

c) Reviews, Editorials, Guidelines

96. **Schön MP**: Predicting the unpredictable: autoantibody profile as parameter to foretell individual responses to infliximab treatment? *Brit. J. Dermatol.* 165(6), 1160-1161, 2011
97. Sterry W, Burgdorf W, Goerdt S, **Schön MP**: Hello - Goodbye. *J. Dtsch. Dermatol. Ges.* 9(12), 993, 2011
98. Emmert B, Hallier E, **Schön MP**, Emmert S: Disease management guidelines in dermatology: Implementation, potentials and limitations exemplified by the guidelines for the management of hand eczema. *Hautarzt* 62(4), 308-314, 2011
99. Wollenberg A, Bieber T, Dirschka T, Luger T, Meurer M, Proksch E, **Schön MP**, Schwarz T, Thaci D, Zuberbier T, Werfel T: Periorale Dermatitis (Leitlinie der Deutschen Dermatologischen Gesellschaft, Entwicklungsstufe 2), *J. Dtsch. Dermatol. Ges.* 9(5), 422-427, 2011
100. Mössner M, Wilsmann-Theiss D, **Schön MP**: Ustekinumab. *Internist. Praxis.* 51, 163-170, 2011
101. Mössner M, Wilsmann-Theiss D, **Schön MP**: Ustekinumab (Stelara). *Arzneimittel-, Therapiekritik.* 43(1), 27-33, 2011
102. Emmert B, Hallier E, **Schön MP**, Emmert S: Xeroderma pigmentosum (XP): A genetic disease sheds light on UV-induced skin cancer. *Hautarzt* 62(2), 91-97, 2011

Publications in the year 2010

a) Experimental original publications

103. Erpenbeck L, Nieswandt B, Schön M, Pozgajova M, **Schön MP**: Inhibition of platelet GPIIb/IIIa and promotion of melanoma metastasis. *J. Invest. Dermatol.* 130(2), 576-586, 2010
104. Amschler K*, **Schön MP***, Pletz N, Wallbrecht K, Erpenbeck L, Schön M: NF- κ B inhibition through proteasome inhibition or IKK β blockade increase the susceptibility of melanoma cells to cytostatic treatment *via* distinct pathways. *J. Invest. Dermatol.* 130(4), 1073-1086, 2010; *equal contribution
105. Hautz T, Zelger B, Grahammer J, Krapf C, Amberger A, Brandacher G, Landin L, Müller HG, **Schön MP**, Cavadas P, Lee AWP, Pratschke J, Margreiter R, Schneeberger S: Investigating molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. *Am. J. Transplant.* 10(5), 1200-1209, 2010
106. Singh TP, **Schön MP**, Wallbrecht K, Michaelis K, Rinner B, Mayer G, Schmidbauer U, Strohmeier H, Wang X-J, Wolf P: 8-methoxypsoralen therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3⁺ Tregs involving CTLA4 signaling in a psoriasis-like skin disorder. *J. Immunol.* 184(12), 7257-7267, 2010
107. Michaelis K, Wallbrecht K, Kerstan A, Beyersdorf N, Williams C, Kerkau T, Wang XJ, Hünig T, **Schön MP**: Modulating T cell functions does not alleviate chronic inflammatory skin lesions in K5.TGF β 1 transgenic mice. *Exp. Dermatol.* 19(5), 406-415, 2010
108. Erpenbeck L, Nieswandt B, Schön M, Pozgajova M, **Schön MP**: Inhibition of platelet GPIIb/IIIa and promotion of melanoma metastasis. *J. Invest. Dermatol.* 130(2), 576-586, 2010
109. Haenssle HA, Riedl P, Buhl T, Schardt A, Rosenberger A, **Schön MP**, Schirmbeck R: Intracellular delivery of major histocompatibility complex class I-binding epitopes: dendritic cells loaded and matured with cationic peptide/poly(I:C) complexes efficiently activate T cells. *Exp. Dermatol.* 19(1), 19-28, 2010
110. Knudsen S, Schardt A, Buhl T, Boeckmann L, **Schön MP**, Neumann C, Haenssle HA: Enhanced T cell activation by immature dendritic cells loaded with HSP70-expressing heat-killed melanoma cells. *Exp. Dermatol.*, 19(2) 108-116, 2010

b) Clinical publications

111. Hänssle HA, Korpas B, Hansen-Hagge C, Buhl T, Kaune KM, Rosenberger A, Krueger U, **Schön MP**, Emmert S: Seven-point checklist for dermoscopy: Performance during 10 years of prospective surveillance of patients at increased melanoma risk. *J. Am. Acad. Dermatol.* 62(5), 785-793, 2010
112. Hänssle HA, Korpas B, Hansen-Hagge C, Buhl T, Kaune KM, Johnsen S, Rosenberger A, **Schön MP**, Emmert S: Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. *Arch. Dermatol.* 146(3), 257-264, 2010

113. Jung AG, Bertsch HP, **Schön MP**, Lippert U: A rare case of sclerodermoid chronic graft versus host disease: Successful treatment with extracorporeal photopheresis. *Hautarzt* 61, 514-517, 2010
114. Kaune KM, Haas E, **Schön MP**, Zutt M: Multiple basal cell carcinomas arising in radiotherapy-treated naevus flammeus: early detection facilitated by 595-nm pulsed dye laser. *Eur. J. Dermatol.* 20(4), 510-511, 2010
115. Sieblist C, Wienrich BG, **Schön MP**, Zutt M: Ausgedehnte Lungenembolie bei Varikophlebitis. *Hautarzt* 61(11), 973-975, 2010
116. Wienrich BG, Bertsch HP, **Schön MP**, Emmert S: Dark grey hyperpigmentation on the face and neck. *J. Dtsch. Dermatol. Ges.* 8(7), 544-546, 2010
117. Buhl T, Wienrich BG, Sieblist C, **Schön MP**, Seitz CS: Development of segmental superficial actinic porokeratosis during immunosuppressive therapy for pemphigus vulgaris. *Acta Derm-Venerol.* 90(2), 212-213, 2010
118. Mousa W, Kues K, Haas E, Lauerer P, Pavlakovic H, **Schön MP**, Zutt M: Successful treatment of a large haemangioma in an infant by propranolol. *J. Dtsch. Dermatol. Ges.* 8(3), 184-186, 2010

c) Reviews, Editorials, Guidelines

119. Boehncke WH, Boehncke S, **Schön MP**: Managing comorbid disease in patients with psoriasis. *Brit. Med. J.* 340: b5666, 2010
120. Erpenbeck L, **Schön MP**: Deadly allies: the fatal interplay between platelets and metastasizing tumor cells. *Blood*, 115(17), 3427-3436, 2010
121. Wozel G, Sticherling M, **Schön MP**: Cutaneous side effects of inhibition of VEGF signal transduction. *J. Dtsch. Dermatol. Ges.* 8(4), 243-249, 2010

Publications in the year 2009

a) Experimental original publications

122. Alban S, Ludwig RJ, Bendas G, **Schön MP**, Oostingh GJ, Radeke HH, Fritzsche J, Pfeilschifter J, Kaufmann R, Boehncke WH: PS3, a semisynthetic b-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. *J. Invest. Dermatol.* 129, 1192-1202, 2009
123. Boeckmann L, Schirmer M, Rosenberger A, Thoms KM, Gutzmer R, Has C, Kunz M, Kuschal C, Laspe P, Struever, **Schön MP**, Brockmoeller J, Emmert S: Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians. *Pharmacogenet. Genomics* 19 (10), 760-769, 2009
124. Ludwig RJ, Hardt K, Hatting, M, Bistrrian R, Diehl S, Radeke H, Podda M, **Schön MP**, Kaufmann R, Henschler R, Pfeilschifter J, Santoso S, Boehncke WH: Junctional

adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. *Immunology* 128(2), 196-205, 2009

125. Giegold O, Ludwig RJ, Hardt K, Will J, **Schön MP**, Oostingh GJ, Pfeilschifter JM, Boehncke WH, Radeke HH: Computer-aided analysis of cell interactions under dynamic flow conditions. *Exp. Dermatol.* 18, 238-245, 2009

b) Clinical publications

126. Kaune KM, Baumgart M, Gesk S, Middel P, Ghadimi BM, Siebert R, Bertsch HP, **Schön MP**, Neumann C: Secondary cutaneous vasculitis like MALT lymphoma with an IGL-MYC fusion. *Arch. Dermatol.* 145, 955-958, 2009
127. Haenssle HA, Kaune KM, Buhl T, Thoms KM, Padeken M, Emmert S, **Schön MP**: Melanoma arising in segmental nevus spilus: Early detection with sequential digital dermoscopy. *J. Am. Acad. Dermatol.* 61(2), 337-341, 2009
128. Buhl T, Bertsch HP, Kaune KM, Mitteldorf C, **Schön MP**, Kretschmer L: Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides. *Clin. Lymphoma Myeloma* 9, E21-E24, 2009
129. Buhl T, Bertsch HP, Raab BW, Kaune KM, Vasko R, Strutz F, **Schön MP**, Lippert U: Fulminant polyarteritis nodosa associated with acute myeloid leukemia resulted in bilateral lower leg amputation. *Rheumatology* 48, 1170-1172, 2009
130. Kaune KM, Baumgart M, Mitteldorf C, Haase D, Ghadimi BM, Bertsch HP, **Schön MP**, Neumann C: Solitary cutaneous nodule of CD4+/CD56+ hematodermic neoplasm progressed to overt leukaemia cutis after chemotherapy: Immunohistology and FISH analysis confirmed the diagnosis. *Am. J. Dermatopath.* 31(7), 695-701, 2009
131. Kaune K, Haas E, Emmert S, **Schön MP**, Zutt M: Successful treatment of severe keratosis pilaris rubra with a 595 nm pulsed dye laser. *Dermatol. Surg.* 35, 1592-1595, 2009
132. Gesierich A, Stoevesandt J, Kneitz C, Bröcker EB, **Schön MP**: Adult-onset Still's disease – an uncommon differential diagnosis of urticaria and treatment with anakinra. *J. Eur Acad. Dermatol.* 23, 104-106, 2009

c) Reviews, Editorials, Guidelines

133. **Schön MP**, Schön M: To die or not to die, that's the question – and the answer may depend on netrin-1. *J. Natl. Cancer Inst.* 101, 217-219, 2009
134. **Schön MP**, Schön M: Topisch applizierte antitumoral wirksame Medikamente – Imiquimod. In: Szeimies RM et al., (Hg.): Tumoren der Haut. Thieme, Stuttgart, 2009
135. **Schön MP**: Neue Systemtherapien in der Dermatologie. In: Ruzicka T, Wolff H, Thomas P, Prinz J (Hg.): Fortschritte der praktischen Dermatologie und Venerologie. Springer-Verlag, Heidelberg, 237-244, 2009

136. Mössner R, **Schön MP**: Medikamentöse Systemtherapien der Psoriasis. CME-Artikel. *Akt. Dermatol.* 36, 142-152, 2009

Publications in the year 2008

a) Experimental original publications

137. Schön M, Wienrich BG, Kneitz S, Schlickum S, Sennefelder H, Amschler K, Vöhringer V, Hüttinger-Kirchhof N, Stiewe T, Ziegelbauer K, **Schön MP**: KINK-1, a novel small-molecule inhibitor of IKK β , and the susceptibility of melanoma cells to antitumoral treatment. *J. Natl. Cancer Inst.* 100, 862-875, 2008
138. Schlickum S, Sennefelder H, Friedrich M, Harms G, Lohse MJ, Kilshaw P, **Schön MP**: Integrin $\alpha_E(CD103)\beta_7$ influences cellular shape and motility in a ligand-dependent fashion. *Blood* 112, 619-625, 2008
139. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, **Schön MP**, Henkler F, Wajant H, Gollnick H, Walczak H, Leverkus M: cFLIP is a critical regulator of TRAIL- or CD95-mediated apoptosis in human melanoma. *Oncogene* 27, 3211-3220, 2008
140. Goodman RS, Kirton CM, Oostingh GJ, **Schön MP**, Clark MR, Bradley JA, Taylor CJ: PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. *Transplantation* 85, 471-477, 2008
141. Dörrie J, Schaft N, Müller I, Wellner V, Schunder T, Hänig J, Oostingh GJ, **Schön MP**, Robert C, Kämpgen E, Schuler G: Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. *Cancer Immunol. Immunother.* 57, 467-477, 2008
142. Wienrich BG, Schuppe HC, **Schön MP**: Expression and putative function of LEEP-CAM (Lymphocyte Endothelial Epithelial-Cell Adhesion Molecule) in human testis. *Andrologia* 40, 252-258, 2008

b) Clinical publication

143. Papavassilis C, de Souza EM, Bröcker EB, **Schön MP**: Rapidly growing nodule on the ear lobe. *J. Dtsch. Dermatol. Ges.* 6, 63-64, 2008

c) Reviews, Editorials, Guidelines

144. **Schön MP**, Schön M: TLR7 and TLR8 as targets in cancer therapy. *Oncogene* 27, 190-199, 2008
145. **Schön MP**: Efalizumab in the treatment of psoriasis. *Clin. Dermatol.* 26, 509-514, 2008

146. **Schön MP**: Animal models of psoriasis – a critical appraisal. *Exp. Dermatol.* 17, 703-712, 2008
147. Li Y, Zollner TM, **Schön MP**: Targeting leukocyte recruitment in the pathogenesis of psoriasis. *Clin. Dermatol.* 26, 527-538, 2008
148. **Schön MP**: Treatment of psoriasis: a journey from empiricism to evidence. *Clin. Dermatol.* 26, 417-418, 2008
149. Seitz CS, **Schön MP**: Hautveränderungen bei rheumatoider Arthritis. *Arthritis und Rheuma* 28, 14-19, 2008
150. Mössner R, **Schön MP**, Reich K: TNF antagonists in the therapy of psoriasis. *Clin. Dermatol.* 26, 486-502, 2008

Publications in the year 2007

a) Experimental original publications

151. Oostingh GJ, Pozgajova M, Ludwig RJ, Krahn T, Boehncke WH, Nieswandt B, **Schön MP**: Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. *Haematol. Hematol. J.* 92, 502-512, 2007
152. Merkle S, Buitrago M, **Schön MP**, Frantz S, Frost RJA, Schmitteckert E, Lohse MJ, Engelhardt S: A role for caspase-1 in heart failure. *Circ. Res.* 100, 645-653, 2007
153. Oostingh GJ, Ludwig RJ, Enders S, Grüner S, Harms G, Boehncke WH, Nieswandt B, Tauber R, **Schön MP**: Diminished lymphocyte adhesion and alleviation of allergic responses by small-molecule- or antibody-mediated inhibition of L-selectin functions. *J. Invest. Dermatol.* 127, 90-97, 2007
154. Oostingh GJ, Schlickum S, Friedl P, **Schön MP**: Impaired induction of adhesion molecule expression in immortalized endothelial cells leads to functional defects in dynamic interactions with lymphocytes. *J. Invest. Dermatol.* 127, 2253-2258, 2007
155. Rattenholl A, Seeliger S, Buddenkotte J, Schön M, **Schön MP**, Vergnolle N, Ständer S, Steinhoff M: Proteinase-activated receptor-2 (PAR2): A tumor suppressor in skin carcinogenesis. *J. Invest. Dermatol.* 127, 2245-2252, 2007

b) Clinical publications

156. Wachter T, Murach WM, Bröcker EB, **Schön MP**: Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by TNF α inhibition. *Brit. J. Dermatol.* 157, 627-629, 2007

157. Kerstan A, Goebeler M, Schmidt E, Bröcker EB, **Schön MP**: Lupus erythematosus profundus in an 8-year-old child. *J. Eur. Acad. Dermatol.* 21, 132-133, 2007

c) Reviews, Editorials, Guidelines

158. Schön M, **Schön MP**: The antitumoral mode of action of imiquimod and other imidazoquinolines. *Curr. Med. Chem.* 14, 681-687, 2007
159. Zollner TM, Asadullah K, **Schön MP**: Targeting leukocyte trafficking to the skin – Still an attractive therapeutic target? *Exp. Dermatol.* 16, 1-12, 2007
160. **Schön MP**, Schön M: Imiquimod – mode of action. *Brit. J. Dermatol.*, 157s, 8-13, 2007
161. **Schön MP**: Psoriasis in the limelight – the remarkable career of an old skin disease. *Clin. Dermatol.* 25, 501-503, 2007
162. Ludwig RJ, **Schön MP**, Boehncke WH: P-selectin – a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. *Exp. Opin. Ther. Targets* 11, 1103-1117, 2007
163. Boehncke WH, **Schön MP**: Animal models of psoriasis. *Clin. Dermatol.* 25, 596-605, 2007

Publications in the year 2006

a) Experimental original publications

164. Wienrich BG, Krahn T, Schön M, Rodriguez ML, Kramer B, Busemann M, Boehncke WH, **Schön MP**: Structure-function relation of efomycines, a family of small-molecule inhibitors of selectin functions. *J. Invest. Dermatol.* 126, 882-889, 2006
165. **Schön MP**, Schön M, Klotz KN: The small anti-tumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and 8-independent fashion. *J. Invest. Dermatol.* 126, 1338-1347, 2006

b) Clinical publication

166. Gesierich A, Herzog S, Grunewald SM, Tappe D, Bröcker EB, **Schön MP**: Eosinophilic folliculitis in a Caucasian patient: Association with toxocariasis? *J. Eur. Acad. Dermatol.* 20, 1317-1321, 2006

c) Reviews, Editorials, Guidelines

167. **Schön MP**, Schön M: The small-molecule immune response modifier imiquimod – Its mode of action and clinical use in the treatment of skin cancer. *Exp. Opin. Ther. Targets* 10; 69-76, 2006

168. **Schön MP**: Pathophysiologie der Psoriasis. *Akt. Dermatol.* 32, 169-175, 2006
169. Benoit S, **Schön MP**: Psoriasis – klinisches Spektrum, Pathogenese und neue Aspekte zur Therapie. *Therapiewoche* 3/4.06, 70-73, 2006
170. **Schön MP**: Die Behandlung der Psoriasis. *Arzneiverordnung in der Praxis* 33. 99-101, 2006
171. Kerstan A, **Schön MP**: Viewpoint: Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells, or keratinocytes? *Exp. Dermatol.* 15, 929, 2006
172. **Schön MP**: Cell adhesion molecules as therapeutic targets. *Exp. Opin. Ther. Targets* 10; 799-802, 2006
173. Wienrich BG, Oostingh GJ, Ludwig RJ, Enders S, Harms G, Tauber R, Krahn T, Kramer B, Boehncke WH, **Schön MP**: Efomycine M: an inhibitor of selectins? (letter). *Nat. Med.* 12, 873-874, 2006
174. **Schön MP**: Molekulare Mechanismen entzündlicher Erkrankungen als Grundlage für selektive Therapien. Jahrbuch der Berlin-Brandenburgischen Akademie der Wissenschaften. 138-145, Akademie-Verlag, Berlin, 2006

Publications in the year 2005 and earlier

a) Experimental original publications

175. Schön M, Kähne T, Gollnick H, **Schön MP**: Expression of gp130 in tumors and inflammatory disorders of the skin: Formal proof of its identity as CD146 (MUC18, Mel-CAM). *J. Invest. Dermatol.* 125, 353-363, 2005
176. Siegmund K, Feuerer M, Siewert C, Ghani S, Haubold U, Dankof A, Krenn V, **Schön MP**, Scheffold A, Lowe JB, Hamann A, Syrbe U, Huehn J: Migration matters: regulatory T cell compartmentalization determines suppressive activity in vivo. *Blood* 106, 3097-3104, 2005
177. Ludwig RJ, Zollner TM, Santoso S, Hardt K, Gille J, Baatz H, Schulze Johann P, Pfeffer J, Radeke HH, **Schön MP**, Kaufmann R, Boehncke WH, Podda M: Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. *J. Invest. Dermatol.* 125, 969-976, 2005
178. **Schön MP**, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, Gollnick H, Schön M: Death receptor-independent induction of apoptosis in malignant melanoma by the small-molecule immune response modifier imiquimod. *J. Invest. Dermatol.* 122, 1266-1276, 2004
179. Ambach A, Bonnekoh B, Nguyen M, **Schön MP**, Gollnick H: Imiquimod, a toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes *in vitro*. *Mol. Immunol.* 40, 1307-1314, 2004

180. Drewniok C, Schön M, Ulrich J, Zen Q, Telen M, Hartig R, Wieland I, Gollnick H, **Schön MP**: Molecular interactions of B-CAM (Basal-Cell Adhesion Molecule) and Laminin in epithelial skin cancer. *Arch. Dermatol. Res.* 296, 59-66, 2004
181. Drewniok C, Schön M, **Schön MP**: Basal-Cell Adhesion Molecule (B-CAM) is inversely associated with apoptosis, but plays a limited role for protection against apoptotic stimuli. *Skin Pharmacol. Physiol.* 17, 304-309, 2004
182. Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, **Schön MP**: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. *J. Natl. Cancer Inst.* 95, 1138-1149, 2003
183. **Schön MP**, Krahn T, Schön M, Rodriguez M-L, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm K-D, Schramm M, Henninger K, Kaufmann R, Gollnick HPM, Parker CM, Boehncke W-H: Efomycine M, a novel specific selectin inhibitor, impairs leukocyte adhesion and alleviates cutaneous inflammation. *Nat. Med.* 8, 366-372, 2002
184. **Schön MP**, Schön M, Parker CM, Williams IR: Dendritic epidermal T cells (DETC) are diminished in α_E (CD103)-deficient mice. *J. Invest. Dermatol.* 119, 190-193, 2002
185. Schön M, Behmenburg C, Ruzicka T, Denzer D, **Schön MP**: Pathogenic function of IL-1 β in psoriasiform skin lesions of Flaky Skin (*fsn/fsn*) mice. *Clin. Exp. Immunol.* 123, 505-510, 2001
186. Rossiter H, Beissert S, Mayer C, **Schön MP**, Wienrich BG, Tschachler E, Kupper TS: Targeted expression of bcl-2 to murine basal keratinocytes results in paradoxical retardation of UVB and DMBA/PMA induced tumorigenesis. *Cancer Res.* 61, 3619-3626, 2001
187. Pauls K, Schön M, Kubitzka R, Homey B, Wiesenborn A, Lehmann P, Ruzicka T, **Schön MP**: Role of integrin α_E (CD103) β_7 for tissue-specific epidermal localization of CD8⁺ T lymphocytes. *J. Invest. Dermatol.* 117, 569-575, 2001
188. Schön M, **Schön MP**: Expression of B-CAM (Basal-Cell Adhesion Molecule) is associated with immature states of human keratinocytes. *J. Invest. Dermatol.* 117, 995-997, 2001
189. Schön M, Denzer D, Kubitzka R, Ruzicka T, **Schön MP**: Critical role of neutrophils for the generation of psoriasiform skin lesions in Flaky Skin (*fsn/fsn*) mice. *J. Invest. Dermatol.* 114, 976-983, 2000
190. Meharrar EJ, **Schön MP**, Hassett D, Parker CM, Havran W, Gardner H: Reduced gut intraepithelial lymphocytes in VLA-1 null mice. *Cell. Immunol.* 201, 1-5, 2000
191. **Schön MP**, Schön M, Warren HB, Donohue JP, Parker CM: Cutaneous inflammatory disorder in integrin α_E (CD103) deficient mice. *J. Immunol.* 165, 6583-6589, 2000

192. Schön M, Klein CE, Hogenkamp V, Kaufmann R, Wienrich BG, **Schön MP**: Basal-Cell Adhesion Molecule (B-CAM) is induced in epithelial skin tumors and inflammatory epidermis, and is expressed at cell-cell- and cell-substrate contact sites. *J. Invest. Dermatol.* 115, 1047-1053, 2000
193. **Schön MP**, Arya A, Murphy EA, Adams CM, Strauch U, Agace WW, Her H, Olson S, LeFrancois L, Brenner MB, Grusby MJ, Parker CM: Mucosal T lymphocyte distribution is altered in integrin α_E (CD103) deficient mice. *J. Immunol.* 162, 6641-6649, 1999
194. Shieh C-C, Sadasivan B, Russell GJ, **Schön MP**, Parker CM, Brenner MB: Lymphocyte adhesion to epithelia and endothelia mediated by the LEEP-CAM glycoprotein. *J. Immunol.* 163, 1592-1601, 1999
195. Lefrancois L, Parker CM, Olson S, Muller W, Wagner N, **Schön MP**, Puddington L: The role of $\beta 7$ integrins in CD8 T cell trafficking during an antiviral immune response. *J. Exp. Med.* 189, 1631-1638, 1999
196. Detmar M, Brown LF, **Schön MP**, Elicker BM, Richard L, Velasco P, Fukumura D, Monsky W, Claffey KP, Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. *J. Invest. Dermatol.* 111, 1-6, 1998
197. **Schön MP**, Detmar M, Parker CM: Murine psoriasis-like disorder induced by naive CD4⁺ T cells. *Nat. Med.* 3: 183-188, 1997
198. Almond-Roesler B, Schön M, **Schön MP**, Blume-Peytavi U, Sommer C, Löster K, Orfanos CE: Cultured dermal papilla cells of the rat vibrissa follicle. Proliferative activity, adhesion properties and reorganization of the extracellular matrix in vitro. *Arch. Dermatol. Res.* 289, 698-704, 1997
199. Schön M, **Schön MP**, Geilen CC, Hoffmann M, Hakyi N, Orfanos CE, Reutter W: Cell-matrix interactions of normal and transformed human keratinocytes in vitro are modulated by the synthetic phospholipid analogue hexadecylphosphocholine. *Brit. J. Dermatol.* 135: 696-703, 1996
200. Schön M, **Schön MP**, Kühröber A, Schirmbeck R, Kaufmann R, Klein CE: Expression of the human $\alpha 2$ integrin subunit in mouse melanoma cells confers the ability to undergo collagen-directed adhesion, migration, and matrix-reorganization. *J. Invest. Dermatol.* 106: 1175-1181, 1996
201. **Schön MP**, Orfanos CE: Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T-16 antigen (Trop-2, MOv16). *Int. J. Cancer* 60: 88-92, 1995
202. **Schön MP**, Blume U, Schön M, Orfanos CE: The human hair follicle: Glycoprotein-related antigenic profile of distinct keratinocytic populations in vivo and their alterations in vitro. *Arch. Dermatol. Res.* 287: 591-598, 1995
203. **Schön MP**, Schön M, Klein CE, Kaufmann R, Herzberg F, Schmidt R, Orfanos CE: Properties of the carcinoma-associated antigen MH99 / KS1/4 in normal and transformed human keratinocytes: Regulation of synthesis, molecular crosslinking, and ultrastructural localization. *Brit. J. Dermatol.* 133: 176-185, 1995

204. **Schön MP**, Limat A, Hartmann B, Klein CE: Characterization of an 80 kD membrane glycoprotein of human keratinocytes: A marker for commitment to terminal differentiation in vivo and in vitro. *J. Invest. Dermatol.* 105: 418-425, 1995
205. Blume U, **Schön MP**, Zouboulis C, Detmar M, Orfanos CE: Vellus-hair derived keratinocyte culture: A new experimental model in human hair research. *Skin Pharmacol.* 7: 27-32, 1994
206. **Schön MP**, Schön M, Klein CE, Blume U, Bisson S, Orfanos CE: Carcinoma-associated 38 kD membrane glycoprotein MH99 / KS1/4 is related to proliferation and age of transformed epithelial cell lines. *J. Invest. Dermatol.* 102: 987-991, 1994
207. **Schön MP**, Schön M, Mattes MJ, Stein R, Weber L, Alberti S, Klein CE: Biochemical and immunological characterization of the human carcinoma-associated antigen MH99 / KS1/4. *Int. J. Cancer.* 55: 988-995, 1993
208. Klein CE, Hartmann B, **Schön MP**, Weber L, Alberti S: Expression of a 38-kD cell surface glycoprotein in transformed human keratinocyte cell lines, basal cell carcinomas, and epithelial germs. *J. Invest. Dermatol.* 95: 74-82, 1990

b) Clinical publications

209. Bong AB, Bonnekoh B, **Schön MP**, Gollnick H: Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa. *J. Am. Acad. Dermatol.* 52, 20-23, 2005
210. Auth M, Wienrich BG, Bauer B, Seitz CS, Bröcker EB, **Schön MP**: Striate urticarial erythemas on trunk and extremities. *J. Dtsch. Dermatol. Ges.* 3, 812-814, 2005
211. Bong AB, Gollnick H, **Schön MP**: Treatment of vitiligo with topical imiquimod. *J. Eur. Acad. Dermatol. Venereol.* 18, 741-742, 2004
212. Ulrich J, Bonnekoh B, Schön M, **Schön MP**, Steinke R, Rössner A, Gollnick H: Prognostic significance of improved detection of micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies – Lessons from 306 consecutive melanoma patients. *Eur. J. Cancer* 40, 2812-2819, 2004
213. Drewniok C, **Schön MP**, Krause M, Gollnick H: Secret miners pull the trigger: Scabies underlying recalcitrant Darier's disease. *J. Dtsch. Dermatol. Ges.* 1, 722-724, 2003
214. Megahed M, Schön M, Selimovic D, **Schön MP**: Reliability of diagnosis of melanoma in situ. *Lancet* 359, 1921-1922, 2002
215. Bong AB, Bonnekoh B, Franke I, **Schön MP**, Ulrich J, Gollnick H: Imiquimod, a new immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. *Dermatology* 205, 135-138, 2002
216. **Schön MP**, Ruzicka T, Wienecke R, Fackler I, Lehmann P: Multiple eruptive angiofibromas of the trunk. A new entity? *Arch. Dermatol.* 137, 1533-1535, 2001

217. **Schön MP**, Heisterkamp T, Reifenberger J, Ruzicka T: Pityriasis rubra pilaris – Therapie mit Acitretin. *Z. Hautkr.* 75, 176-178, 2000
218. Malek L, **Schön MP**, Grewe M, Lehmann P, Megahed M: (Muko)-Kutane Leishmaniose. *Z. Hautkr.* 75, 185-186, 2000
219. Reifenberger J, **Schön MP**, Becker-Wegerich P, Krutmann J, Grewe M: Kontaktsensibilisierung auf inhalative Kortikosteroide. *Z. Hautkr.* 75, 187-188, 2000
220. **Schön MP**, Heisterkamp T, Ahrens C, Megahed M, Ruzicka T: Prästernales verruköses Karzinom. *Hautarzt* 51, 766-769, 2000
221. **Schön MP**, Reifenberger J, Gantke B, Megahed M, Lehmann P: Progressive vernarbende Alopezie bei AIDS. *Hautarzt* 51, 935-938, 2000
222. **Schön MP**, Reifenberger J, Eberhardt A, Grewe M: Epikutantestung zur Diagnostik von Arzneimittel-Reaktionen. *Z. Hautkr.* 75, 599-600 2000
223. Eberhardt A, Reifenberger J, Bruch-Gerharz D, **Schön MP**, Becker-Wegerich P, Ruzicka T: Herpes vegetans. *Z. Hautkr.* 75, 595-596, 2000
224. Reifenberger J, **Schön MP**, Lehmann P: Lineare Trichoepitheliome mit assoziierten Basalzellkarzinomen. *Z. Hautkr.* 75, 592-593, 2000
225. Richter-Hintz D, von Schmiedeberg S, Bruch-Gerharz D, **Schön MP**, Reifenberger J, Grewe M, Ruzicka T: Pyoderma gangraenosum der Mund- und Rachenschleimhaut. *Z. Hautkr.* 75, 588-590, 2000
226. **Schön MP**, Brunner M, Ruzicka T, Megahed M: Psoriasis capitis with scarring alopecia. *Cosmet. Dermatol.* 14, 29-32, 2000
227. **Schön MP**, Reifenberger J, von Schmiedeberg S, Megahed M, Lang K, Gattermann N, Meckenstock G, Goerz G, Ruzicka T: Multiple basal cell carcinomas associated with hairy cell leukemia. *Brit. J. Dermatol.* 140, 150-153, 1999
228. **Schön MP**, Reifenberger J, Bruch-Gerharz D, Lehmann P: Papulosis maligna atrophicans (M. Köhlmeier-Degos). *Z. Hautkr.* 74, 233-235, 1999
229. Reifenberger J, **Schön MP**, Bruch-Gerharz D, Lehmann P, Ruzicka T: Psoriatische Onycho-Pachydermo-Periostitis. *Z. Hautkr.* 74, 237-238, 1999
230. Reifenberger J, Kruse R, **Schön MP**, Megahed M, Lehmann P: Incontinentia pigmenti bei einem männlichen Säugling. *Z. Hautkr.* 74, 578-579, 1999
231. **Schön MP**, Tebbe B, Trautmann C, Orfanos CE: Lichenoid drug eruption induced by spironolactone. *Acta Derm.-Venereol.* 74: 476, 1994

c) Reviews, Editorials, Guidelines

232. **Schön MP**, Boehncke WH: Psoriasis. *New Engl. J. Med.* 352, 1899-1912, 2005

233. **Schön MP**: Advances in psoriasis treatment. *Lancet* 366, 1333-1335, 2005
234. **Schön MP**, Ludwig R: Leukocyte trafficking to inflamed skin – molecular mechanisms and implications for therapeutic target molecules. *Exp. Opin. Ther. Targets* 9, 225-243, 2005
235. **Schön MP**: Leukocyte extravasation as a target for anti-inflammatory therapy – which molecule to choose? *Exp. Dermatol.* 14, 74-76, 2005
236. **Schön MP**: Inhibitors of selectin functions in the treatment of inflammatory skin disorders. *Ther. Clin. Risk Manag*, 1, 201-208, 2005
237. **Schön MP**, Boehncke WH, Bröcker EB: Psoriasis – clinical manifestations, pathogenesis and therapeutic perspectives. *Discov. Med.* 5, 253-258, 2005
238. **Schön MP**, Boehncke WH: Psoriasis (letter). *N. Engl. J. Med.* 353, 849-850, 2005
239. **Schön MP**: The role of T lymphocytes in skin biology. In: Boehncke WH (Hg.): Lymphocyte homing to the skin – Immunology, immunopathology, and therapeutic perspectives. CRC Press, Boca Raton; 1-28, 2005
240. **Schön MP**: Cutaneous lymphocyte localization in the pathogenesis of psoriasis. *Ernst Schering Res Found Workshop* 44, 27-51, 2004
241. **Schön MP**, Schön M: Immune Modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod. *Apoptosis* 9, 291-298, 2004
242. **Schön MP**, Drewniok C, Boehncke WH: Targeting selectin functions in the pathogenesis of psoriasis. *Curr. Drug Targets* 3, 163-168, 2004
243. Boehncke WH, **Schön MP**: Interfering with leukocyte rolling – a promising therapeutic approach in inflammatory skin disorders? *Trends Pharmacol. Sci.* 24, 49-52, 2003
244. **Schön MP**, Zollner TM, Boehncke WH: The molecular basis of lymphocyte recruitment to the skin - clues for pathogenesis and selective therapies of inflammatory disorders. *J. Invest. Dermatol.* 121, 951-962, 2003
245. **Schön MP**, Boehncke WH: Efomycine: Anti-entzündliche Therapie durch Hemmung der Leukozyten-Endothelzell-Interaktion. *Akt. Dermatol.* 29, 431-434, 2003
246. Reifenberger J, **Schön MP**: Molekulare Grundlagen und pathogeneseorientierte Therapie epithelialer Tumoren der Haut. *Hautarzt* 54, 1164-1170, 2003
247. **Schön MP**, Ruzicka T: Psoriasis: The plot thickens *Nat. Immunol.* 2, 91, 2001
248. **Schön MP**: Krankheiten des subkutanen Fettgewebes. In: Orfanos CE, Garbe C (eds.): Therapie der Hautkrankheiten. Springer-Verlag, Berlin, pp. 643-658, 1995; 2. Überarb. Aufl. 2002
249. **Schön MP**: Is psoriasis a T cell disease? *Exp. Dermatol.* 9, 373-374, 2000

250. **Schön MP**, Ruzicka T: Retinoid – ultraviolet light-combinations for the treatment of psoriasis. *Retinoids Lipid-Soluble Vit. Clin. Pract.* 16, 60-64, 2000
251. **Schön MP**: Animal models of psoriasis – what can we learn from them? *J. Invest. Dermatol.* 112, 405-410, 1999
252. **Schön MP**, Goerz G: Haut und Leber - Pathophysiologische Grundlagen und diagnostische Wertigkeit von Hautsymptomen bei Lebererkrankungen. *Z. Hautkr.* 73, 72-82, 1998
253. **Schön MP**, Parker CM: A T-cell-initiated murine model of inflammatory skin lesions. *Retinoids Lipid-Soluble Vit Clin Pract* 13, 128-131, 1997
254. **Schön MP**, Parker CM: Animal models of psoriasis (letter). *Nat. Med.* 3, 475-476, 1997